Recent share performance

Bausch + Lomb (NYSE:BLCO) has drawn investor attention after recent share performance, with the stock roughly flat over the past day, slightly lower over the past week, and down over the past month and past 3 months.

At a share price of $15.65, Bausch + Lomb’s short term momentum has softened, with the 30 day share price return down 4.05% and the 90 day share price return down 14.99%. At the same time, the 1 year total shareholder return sits at 36.44%, highlighting a gap between recent sentiment and the longer term experience for investors.

If this mix of short term weakness and solid 1 year total shareholder return has you thinking about where else the market might be mispricing risk and potential, it could be a good time to scan 40 healthcare AI stocks

With Bausch + Lomb trading at $15.65, sitting at a discount to analyst targets and an indicated intrinsic value, the key question is whether this gap signals an undervalued stock or whether the market is already pricing in future growth.

Most Popular Narrative: 60.1% Undervalued

According to the most followed narrative on Bausch + Lomb, a fair value of $39.23 sits well above the recent $15.65 share price, framing the stock as heavily discounted in that analysis.

After reviewing historical filings, industry norms, and comparable companies:

A. This delay is unprecedented for this company.

There is no prior instance of an AGM result blackout of this length.

B. This delay is highly unusual for any public company.

AGM results are procedural, routine, and expected.

C. The lack of communication increases governance risk.

Shareholders cannot assess leadership legitimacy without vote results.

D. The silence itself becomes material.

When a company withholds information that is normally disclosed, the absence of disclosure becomes a signal.

The fair value in this narrative leans on specific assumptions for revenue growth, future profit margins, and the rate used to discount cash flows back to today. Want to see how those pieces fit together and why they point to a value so far above the current price? The full narrative lays out the numbers and the reasoning in detail.

Result: Fair Value of $39.23 (UNDERVALUED)

However, this undervalued view could be challenged if governance concerns around AGM disclosure persist, or if the current net loss of US$219 million weighs more heavily on sentiment.

Next Steps

Given this mix of concerns and potential rewards, it makes sense to move quickly, review the core facts, and shape your own view using the 3 key rewards.

Looking for more investment ideas?

If Bausch + Lomb is on your radar, do not stop there. Use the screener to uncover other opportunities that could round out your watchlist.

• Spot potential value plays early by scanning 46 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect their prospects.
• Prioritise resilience by reviewing 63 resilient stocks with low risk scores that score well on stability so you are not relying on just one stock for steadier performance.
• Hunt for future standouts by researching the screener containing 22 high quality undiscovered gems before the crowd pays attention and quality stories become crowded trades.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.